Navigation Links
Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief
Date:1/28/2009

HONOLULU, Jan. 28 /PRNewswire/ -- Researchers at Brigham and Women's Hospital found that patients taking cannabinoid medicines for pain may be getting "high," but these effects were unrelated to relief from their pain symptoms. Results of their study, one of the first to examine the addictive potential of this class of pain medicine, were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

In the study, Ajay Wasan, MD MSc and colleagues found that when used for non-cancer pain management, the cannabinoid class of medicines (such as dronabinol), got patients "high," but the majority of subjects experienced significant pain relief independent of these psychoactive effects. Results indicate that these medicines have the likelihood of an addiction similar to smoking marijuana, leading researchers to conclude the abuse potential of this class should be studied further.

Using the Addiction Research Center Inventory (ARCI), the gold-standard for determining the abuse liability of substances, Dr. Wasan and colleagues at McLean Hospital looked at two different patient populations to compare the effects of medicinal, synthetic cannabinoid and marijuana. The first population was suffering from pain, and took each of the following at separate visits where they were observed for eight hours: placebo, 10mg, or 20 mg of dronabinol. The second population was not suffering from pain, but they were monitored every 30 minutes after smoking a high and low strength marijuana cigarette. Participants in both populations were given the ARCI every hour. After two hours, patients in the first population (synthetic cannabinoid medicine) were found to have the same psychoactive effects that patients from the second population (smoked marijuana) did after 30 minutes.

"Based on our study we believe the addictive qualities of this class of medicines need more investigation. In our study, patients taking the medicine, like the patients smoking the marijuana, were, essentially, stoned. However, they didn't report less pain, indicating the pain relief properties were independent of the psychoactive effects," said Dr. Wasan, lead author of the study, and director of clinical pain research at Brigham and Women's Hospital. "We discovered that both the synthetic cannabinoid medicines we studied and marijuana have similar psychoactive properties and suggestive of an addiction potential."

    Poster Session Information (Poster 193)
    Begins: 3:30 PM (Hawaiian Time), Wednesday, January 28, 2009
    Ends:  10:00 AM (Hawaiian Time), Thursday, January 29, 2009
    Location:  Coral Ballroom Foyer, Hilton Hawaiian Village

About the AAPM

For more than 25 years, the American Academy of Pain Medicine (AAPM) has been the medical specialty society representing more than 2,200 physicians practicing in the field of pain medicine. The Academy is involved in education, training, advocacy and research in the specialty of pain medicine. Information is available on the practice of pain medicine at http://www.painmed.org.


'/>"/>
SOURCE American Academy of Pain Medicine
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
2. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
3. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
4. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
5. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
6. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
7. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
8. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
9. VA-NIH Study Offers Hope for Parkinsons Patients
10. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
11. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... -- MJAC2017 , the premier cannabis event devoted to ... its leading lineup. MJAC2017 is proud ... specializing in the development of pharmaceutical and consumer products, will ... The Green Organic Dutchman are gold sponsors for the event, ... ...
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and Gulf ... Houston, Texas . The Mostyn Law family ... 2 years. That is why Mostyn Law is partnering ... to show its appreciation. Blood supplies are running ... 5% short of hospital needs in August. That is why the ...
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive at ... Trustees for a three-year term beginning January 1, 2018. , The AHA ... committed to the improvement of health in their communities. Founded in 1898, the AHA ...
(Date:8/20/2017)... Sugar Land Texas (PRWEB) , ... August 20, ... ... to announce that the HIPAA ComplyPAK™ Compliance Management System has assisted ... American Institute of Certified Public Accountants, Service Organization Control Level 2 (AICPA SOC ...
(Date:8/19/2017)... ... 18, 2017 , ... Paragon and IOTA ... help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s unique approach ... with lower fees. Paragon will build a fully verifiable database to track prescriptions, ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
(Date:8/18/2017)... VA (PRWEB) , ... August 18, 2017 , ... More ... the Democratic Republic of Congo (DRC) thanks to an ambitious venture that conjoined the ... well as the generous support of the Liberty community. These shoes will save lives ...
Breaking Medicine News(10 mins):